Xintian Pharma’s Financial Performance and Shareholder Updates

Xintian Pharma, a company listed on the Shenzhen Stock Exchange, has recently released its financial results for the first half of 2025, revealing significant challenges in its financial performance. The company’s close price on July 29, 2025, was 10.99 CNY, with a market capitalization of 1.97 billion CNY. The price-to-earnings ratio stood at 37.04, reflecting investor sentiment amid the company’s financial results.

Financial Performance Overview

For the first half of 2025, Xintian Pharma reported a revenue of approximately 3.58 billion CNY, marking an 18.88% decrease compared to the same period last year. The net profit attributable to shareholders was approximately 576.61 million CNY, a significant drop of 80.99% year-over-year. The second quarter alone saw a 37.5% decrease in revenue and an 89.3% decrease in net profit attributable to shareholders. The company attributed these declines to increased production costs driven by rising raw material prices, as well as adverse market conditions.

Operational Highlights

Despite the downturn in profitability, Xintian Pharma’s operational cash flow showed a positive trend, with a net increase of 6.719 billion CNY, up 106.9% year-over-year. The EPS (fully diluted) was reported at 0.0236 CNY. The company’s financial health over the past five years has been generally below industry averages, with average growth, debt repayment, and profitability capabilities, but strong asset quality and cash flow.

Shareholder Changes

In recent developments, Xintian Pharma’s top ten shareholders have seen changes, with six new entrants and six exits. Notably, the new top ten shareholders include:

• 诺安多策略混合A: Holding 107.3 thousand shares, accounting for 0.45% of the circulating shares.
• 俞佳男: Holding 102.7 thousand shares, accounting for 0.43%.
• 嵇方一: Holding 95.42 thousand shares, accounting for 0.4%.
• UBS AG: Holding 94.12 thousand shares, accounting for 0.39%.
• 方微: Holding 89.91 thousand shares, accounting for 0.38%.
• 李秀景: Holding 83.68 thousand shares, accounting for 0.35%.

Corporate Governance Updates

On July 29, 2025, Xintian Pharma held its first board meeting of the eighth term, where Ding Lian was elected as the chairman of the board, and Wang Jinhua as the vice-chairman. Both positions are aligned with the term of the eighth board of directors. Additionally, the company announced the release of certain shares from collateral by the controlling shareholder.

These updates reflect Xintian Pharma’s ongoing efforts to navigate financial challenges and restructure its shareholder base amidst a challenging market environment.